Hepatitis B accounts for the majority of viral hepatitis patients in China, and HBeAg (+) and/or high HBVDNA load and significantly elevated ALT are significant risk factors for the development of primary hepatocellular carcinoma, so antiviral therapy is very important in the treatment of hepatitis B. At present, nucleoside analogs are often used in clinical practice, such as lamivudine, adefovir, telbivudine, and entecavir. At present, the nucleoside analogues frequently used in clinical practice are: lamivudine, adefovir, telbivudine, entecavir, etc. The effectiveness of their antiviral therapy has been recognized, and with the continuous enrichment of the experience of using them in clinical practice, the development trend of them is as follows: 1) Evolution from sequential therapy to combination therapy 2) Evolution from short course of therapy to long course of therapy 3) Emphasis on the patient’s adherence and optimization of the treatment 4) Adjustment of the medications It is recommended to check the HBVDNA gene sequencing when